Trial Profile

Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled Study

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nipocalimab (Primary)
Indications Autoimmune haemolytic anaemia
Focus Proof of concept; Registrational; Therapeutic Use
Acronyms ENERGY
Sponsors Janssen Research & Development; Janssen-Cilag; Momenta Pharmaceuticals

Most Recent Events

09 Dec 2024 According to Johnson and Johnson media release, the company look forward to sharing the results of our Phase 2/3 study in 2025.
15 Aug 2023 Planned End Date changed from 27 Dec 2027 to 10 Apr 2028.
02 May 2023 Planned End Date changed from 14 Dec 2027 to 27 Dec 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com